According to reports, XUANZHUBIO-B (02575) experienced a significant increase of over 14% in the afternoon session, reaching a high of HKD 38.8, over 234% above its IPO price of HKD 11.6. As of the latest update, the stock was up 12.12% at HKD 38.12, with a trading volume of HKD 32.29 million. The prospectus indicates that XUANZHUBIO is a spin-off from the Hong Kong-listed company Sihuan Pharmaceutical (00460), characteristic of “H-share拆H.” As of the final feasible date, XUANZHUBIO has more than ten drug assets actively in development, covering digestive system diseases, tumors, and non-alcoholic steatohepatitis (NASH). This includes three NDA-approved assets, one drug project in the NDA registration phase, one in Phase III clinical trials, four in Phase I clinical trials, and five having received IND approval. An analysis highlights that supported by a dual-engine drive of digestive disorders and tumors, XUANZHUBIO is poised for a commercialization explosion in 2025: core tumor drugs Pirocil and Deleuacric have recently received approval, alongside the previously approved core product proton pump inhibitor Anneladazole Sodium, forming a commercial "three-carriage" product matrix. This reflects the industry's and market's recognition of the company's dual strategies of hard-core innovation and commercial development.